Medicare AWP Reform Plan May Be “Politically Untenable,” Amgen Says
Executive Summary
The impact of Medicare's new oncology reimbursement policy will depend on how "average sales price" is defined, Amgen said
You may also be interested in...
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22
Novartis Applauds Medicare Rx Pilot; Overall Bill “Somewhat Negative”
Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs